ADIPOQ and metabolic dysfunction-associated steatotic liver disease: Although there is no proven pharmacotherapy for the treatment of NAFLD, therapeutic strategies to upregulate adiponectin levels, such as TZD administration are expected to be effective for the treatment of the metabolic syndrome including NAFLD (Iwaki et al. 2003; Sharabi et al. 2007).